Differential cytotoxicity of ifosfamide and its metabolites in renal epithelial cell cultures

Toxicology in Vitro

Volumn 12, Issue 3, 1998, Pages 209-217

  Broadhead, C L ^a   Walker, D ^a   Skinner, R ^a   Simmons, N L ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IFOSFAMIDE;

ANIMAL CELL; ANION TRANSPORT; ARTICLE; CATION TRANSPORT; CYTOTOXICITY; DNA ALKYLATION; ENZYME ACTIVITY; EPITHELIUM CELL; HYDROXYLATION; KIDNEY EPITHELIUM; LIVER METABOLISM; NEPHROTOXICITY; NONHUMAN;

EID: 0031851129     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-2333(97)00113-6     Document Type: Article

References (43)

1. Andreoli S. P., McAteer J. A., Seifert S. A., Kempson S. A. Oxidant-induced alterations in glucose and phosphate transport in LLC-PK1 cells: mechanisms of injury. American Journal of Physiology. 265:1993;F377-F384.
2. Blackmore M., Richardson J. C., Coestello S., Harpur E. S., Gray T. J. B. In vitro toxicity of cephalosporin and aminoglycoside antibiotics to LLCPK1 cells assessed by changes in glucose uptake. Toxicology in Vitro. 8:1994;771-773.
3. Brade W. P., Herdrich K., Klein H. O. Ifosfamide - dosing and scheduling. Contributions to Oncology. 26:1987;22-52.
4. Brock N., Hilgard P., Peukert M., Pohl J., Sindermann H. Basis and new developments in the field of oxazaphosphorines. Cancer Investigations. 6:1988;513-532.
5. Caron H. R., Abeling N., van Gennip A., de Kraker J., Voute P. A. Hyperaminoaciduria identifies patients at risk of developing renal tubular toxicity associated with ifosfamide and platinate containing regimens. Medicine and Pediatric Oncology. 20:1992;42-47.
6. Chang T. K. H., Weber G. F., Crespi C. L., Waxman D. J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Research. 53:1993;5629-5637.
7. Charlton H. A., Simmons N. L. Established human renal cell lines: phenotypic characteristics define suitability for use in in vitro models for predictive toxicology. Toxicology in Vitro. 7:1993;129-136.
8. Chen L., Waxman D. J., Chen D. S., Kufe D. W. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Research. 56:1996;1331-1340.
9. Crook T. R., Souhami R. L., Whyman G. D., McLean A. E. M. Glutathione depletion as a determinant of sensitivity of human leukaemia cells to cyclophosphamide. Cancer Research. 46:1986;5035-5038.
10. Dechant K. L., Brogden R. N., Pilkington T., Faulds D. Ifosfamide/Mensa. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs. 42:1991;428-467.
11. Goldring S. R., Dayer J-M., Ausiello D. A., Krane S. M. A cell strain cultured from porcine kidney increases cyclic AMP content upon exposure to calcitonin or vasopressin. Biochemical and Biophysical Research Communications. 83:1978;434-440.
12. Goren M. P., Wright R. K., Pratt C. B., Pell F. E. Dechloroethylation of ifosfamide and neurotoxicity. Lancet. ii:1986;1219-1220.
13. Hori R., Okamura M., Takayama A., Hirozane K., Takano M. Transport of organic anion in the OK kidney epithelial cell line. American Journal of Physiology. 264:1993;F975-980.
14. Hunter J., Hirst B. H., Simmons N. L. Transepithelial secretion, cellular accumulation and cytotoxicity of vinblastine in defined MDCK cell-strains. Biochimica et Biophysica Acta. 1179:1993;1-10.
15. Inui K., Saito H., Hori R. H-gradient-dependent active transport of tetraethylammonium cation in apical membrane vesicles from a kidney epithelial cell-line LLC PK1. Biochemical Journal. 227:1985;199-203.
16. Lind M. J., McGown A. T., Hadfield J. A., Thatcher N. The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochemical Pharmacology. 38:1989;1835-1840.
17. Low J. E., Borch R. E., Sladek N. E. Further studies on the conversion of 4-hydroxyozaphosphorines to reactive mustards in organic buffers. Cancer Research. 13:1983;5815-5820.
18. McGiff J. C., Quilley C. P., Carroll M. A. The contribution of cytochrome P450-dependent arachidonate metabolism to integrated renal function. Steroids. 58:1993;573-579.
19. Malmstrom K., Strange G., Murer H. Identification of proximal tubular transport functions in the established kidney cell-line OK. Biochimica et Biophysica Acta. 902:1987;269-277.
20. Mohrmann M., Ansorge S., Schmich U., Schonfeld B., Brandis M. Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture. Pediatric Nephrology. 8:1994;157-163.
21. Mohrmann M., Ansorge S., Schonfeld B., Brandis M. Dithio-bis-mercaptoethanesulfonate (DIMESMA) does not prevent damage by metabolites of ifosfamide and cyclofosfamide in LLCPK1 cells. Paediatric Nephrology. 8:1994;458-465.
22. Mohrmann M., Kupper N., Schonfeld B., Brandis M. Ifosfamide and MESMA- Effects on the Na/H exchanger activity in renal epithelial cells in culture (LLCPK1). Renal Physiology and Biochemistry. 18:1995;118-127.
23. Mohrmann M., Pauli A., Ritzer M., Schonfeld B., Seifert B., Brandis M. Inhibition of sodium-dependent transport systems in LLC-PK1 cells by metabolites of ifosfamide. Renal Physiology and Biochemistry. 15:1992;289-301.
24. Morel F. Sites of hormone action in the mammalian nephron. American Journal of Physiology. 240:1981;F159-164.
25. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferative and cytotoxicity assays. Journal of Immunological Methods. 65:1983;55-63.
26. Pearcey R., Calver R., Mehta A. Disposition of ifosfamide in patients receiving ifosfamide infusion therapy for the treatment of cervical carcinoma. Cancer Chemotherapy and Pharmacology. 22:1988;353-355.
27. Pinkerton C. R., Rogers H., James C., Bowman A., Barbor P. R. H., Eden O. B., Pritchard J. A phase II study of ifosfamide in children with recurrent solid tumours. Cancer Chemotherapy and Pharmacology. 15:1985;258-262.
28. Schwartzman M. L., Da Silva J. L., Lin F., Nishimura M., Abraham N. G. Cytochrome P450 expression and arachidonate acid omega-hydroxylation in the kidney of the spontaneously hypertensive rat. Nephron. 73:1996;652-663.
29. Simmons N. L. (1990) The tissue culture of established renal cell-lines. In Methods of Enzymology. Vol. 191. Biomembranes Part 5. Cellular and Subcellular Transport: Epithelial cells. Edited by S. Fleischer and B. Fleischer. pp. 426-436. Academic Press, San Diego, CA.
30. Skinner R., Sharkey I. M., Pearson A. D. J., Craft A. W. Ifosfamide, mensa and nephrotoxicity in children. Journal of Clinical Oncology. 11:1993;173-190.
31. Skinner R., Pearson A. D. J., English M. W., Price L., Wyllie R. A., Coulthard M. G. Risk factors for ifosfamide nephrotoxicity in children. Lancet. 348:1996;578-580.
32. Sladek N. E. (1994) Metabolism and pharmacokinetic behaviour of cyclophosphamide and related oxazaphosphorines. In Anticancer Drugs: Reactive Metabolism and Drug Interactions. Edited by G. Powis. pp. 79-156. Pergamon Press, Oxford.
33. Sood C., O'Brien P. J. Molecular mechanisms of chloracetaldehyde-induced cytotoxicity in isolated rat hepatocytes. Biochemical Pharmacology. 46:1993;1621-1626.
34. Sood C., O'Brien P. J. Chloroacetaldehyde-induced hepatocyte cytotoxicity - mechanisms for cytoprotection. Biochemical Pharmacology. 48:1994;1025-1032.
35. Ullrich K. J., Rumrich G., David C., Fritzsch G. Bisubstrates:substances that interact with renal contraluminal organic anion and organic cation transport systems. Pflugers Archives. 425:1993;300-312.
36. Vickers A. E. M., Fisher R. L., Brendel K., Guertler J., Dannecker R., Keller B., Fischer V. Sites of biotransformation for the cyclosporin derivative SDZ IMM125 using human liver and kidney slices and intestine: Comparison with rat liver slices and cyclosporin A metabolism. Drug Metabolism and Disposition. 23:1995;327-333.
37. Vickers A. E. M., Alegret M., Meyer E., Smiley S., Guertler J. Hydroxyethyl cyclosporin A induces and decreases P4503A and P-glycoprotein levels in rat liver. Xenobiotica. 26:1996;27-39.
38. Walker D., Flinois J-P., Monkman S. C., Beloc C., Boddy A. V., Cholerton S., Daly A. K., Lind M. J., Pearson A. D. J., Beaune P. H., Idle J. R. Identification of the major hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochemical Pharmacology. 47:1994;1157-1163.
39. Walker D., Ranu H. K., Pearson A. D. J., Idle J. R. Cytochrome P450 CYP 3A5 makes a significant contribution to the metabolism in vitro of cyclophosphamide and ifosfamide. Proceedings of the American Association for Cancer Research. 373:1996;2225.
40. Weber G. F., Waxman D. J. Activation of the anti-cancer drug ifosfamide by rat liver microsomal P450 enzymes. Biochemical Pharmacology. 45:1993;1685-1694.
41. Yuag H. Y. L., Lee Q. P., Rettie A. E., Juchau M. R. Functional cytochrome P4503A isoforms in human embryonic tissues: Expression during organogenesis. Molecular Pharmacology. 46:1991;922-928.
42. Yuan G., Ott R. J., Salgado C., Giacomini K. Transport of organic cations by a renal epithelial cell line (OK). Journal of Biological Chemistry. 266:1991;8978-8988.
43. Zamlaustitucker M. J., Morris M. E., Springate J. E. Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney. Toxicology and Applied Pharmacology. 129:1994;170-175.